05:51 PM EDT, 03/21/2024 (MT Newswires) -- DiaMedica Therapeutics ( DMAC ) on Thursday filed a registration statement with the US Securities and Exchange Commission for the potential sale of up to $100 million of its securities from time to time in one or more offerings.

The filing covers common shares, warrants and units.

The company said it intends to use the proceeds to fund clinical and product development activities and for other working capital and general corporate purposes.

Price: 2.79, Change: +0.1, Percent Change: +3.72